Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS

Exclusion Criteria

• •• Patient has experienced an ST-segment elevation myocardial infarction within the preceding 48 hours; Patient must have CPK and CK-MB \<3 times upper limit of normal at the time of angioplasty and enrollment;
• •* Previously diagnosed with either type 1 or type 2 diabetes and controlling glucose by one or a combination of the following treatments: diet, oral anti-diabetic agents, or insulin;
• •* Patient had or plans to have CABG within 9 months;
• •* Ejection fraction \<35%; class III-IV CHF;
• •* Active liver disease (ALT \>2.5 times upper limit of normal);
• •* Women who are pregnant;
• •* A platelet count of less than 100,000 cells/mm3;
• •* Impaired renal function (creatinine ≥2.5 mg/dL) or status post renal transplant;
• •* Recipient of heart transplant;
• •* Patient with a life expectancy less than 12 months;
• •* Known allergies to aspirin, clopidogrel bisulfate (PlavixR) and ticlopidine (TiclidR), heparin, bivalirudin, contrast, or pioglitazone, that cannot be medically managed;
• •* Any significant medical condition, which in the investigator's opinion, may interfere with the patient's optimal participation in the study;
• •* Currently participating in an investigational drug or another device study;
• •* Current use of any thiazolidinedione (Rosiglitazone (Avandia) or Poiglitazone (Actos).